

## Purified anti-human CD279 (PD-1) Antibody

<b>Catalog# / Size</b>	329902 / 100 µg
<b>Clone</b>	EH12.2H7
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	PD-1
<b>Isotype</b>	Mouse IgG1, κ
<b>Description</b>	Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

### Product Details

---

<b>Verified Reactivity</b>	Human
<b>Reported Reactivity</b>	African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Mouse
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C.
<b>Application</b>	<a href="#">FC - Quality tested</a> <a href="#">Block, IHC-F - Reported in the literature, not verified in house</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: blocking of ligand binding <sup>1-3</sup> , immunohistochemical staining of paraformaldehyde fixed frozen sections <sup>13</sup> , and spatial biology (IBEX) <sup>15,16</sup> . The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Dorfman DM, <i>et al.</i> 2006 <i>Am. J. Surg. Pathol.</i> 30:802. (FA)</li> <li>2. Radziejcz H, <i>et al.</i> 2007. <i>J. Virol.</i> 81:2545. (FA)</li> <li>3. Velu V, <i>et al.</i> 2007. <i>J. Virol.</i> 81:5819. (FA)</li> <li>4. Zahn RC, <i>et al.</i> 2008. <i>J. Virol.</i> 82:11577. <a href="#">PubMed</a></li> <li>5. Chang WS, <i>et al.</i> 2008. <i>J. Immunol.</i> 181:6707. (FC) <a href="#">PubMed</a></li> <li>6. Nakamoto N, <i>et al.</i> 2009. <i>PLoS Pathog.</i> 5:e1000313. (FA)</li> <li>7. Jones RB, <i>et al.</i> 2009. <i>J. Virol.</i> 83:8722. (FC) <a href="#">PubMed</a></li> <li>8. Vojnov L, <i>et al.</i> 2010. <i>J. Virol.</i> 84:753. (FC) <a href="#">PubMed</a></li> <li>9. Radziejcz H, <i>et al.</i> 2010. <i>J. Immunol.</i> 184:2410. (FC) <a href="#">PubMed</a></li> <li>10. Montero P, <i>et al.</i> 2011. <i>J. Immunol.</i> 186:4618. <a href="#">PubMed</a></li> <li>11. Conrad J, <i>et al.</i> 2011. <i>J. Immunol.</i> 186:6871. <a href="#">PubMed</a></li> <li>12. Salisch NC, <i>et al.</i> 2010. <i>J. Immunol.</i> 184:476. (Rhesus reactivity)</li> </ol>

13. Li H and Pauza CD. 2015. *Eur. J. Immunol.* 45:298. (IHC)
14. Peterson VM, et al. 2017. *Nat. Biotechnol.* 35:936. (PG)
15. Radtke AJ, et al. 2020. *Proc Natl Acad Sci USA.* 117:33455-33465. (SB) [PubMed](#)
16. Radtke AJ, et al. 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Dhariwala MO, et al. 2020. *Cell Rep Med.* 1:100132. [PubMed](#)
2. Zheng G, et al. 2021. *Signal Transduct Target Ther.* 6:236. [PubMed](#)
3. Gernoux G, et al. 2020. *Mol Ther.* 28:747. [PubMed](#)
4. Yonemitsu K, et al. 2022. *Sci Rep.* 12:12007. [PubMed](#)
5. Wagner J et al. 2019. *Cell.* 177(5):1330-1345. [PubMed](#)
6. Tocheva AS, et al. 2020. *J Biol Chem.* 295:18036. [PubMed](#)
7. Lu X, et al. 2018. *Am J Cancer Res.* 8:1564. [PubMed](#)
8. Chakhtoura M, et al. 2021. *PLoS Pathog.* 17:e1009732. [PubMed](#)
9. Mann ER, et al. 2020. *Sci Immunol.* :5. [PubMed](#)
10. Kaufmann M, et al. 2021. *Med.* 2(3):296-312.e8. [PubMed](#)
11. Dean JW, et al. 2020. *J Autoimmun.* 108:102417. [PubMed](#)
12. Kondo H, et al. 2022. *Front Immunol.* 13:836923. [PubMed](#)
13. Hsu DC, et al. 2018. *Clin Infect Dis.* 67:437. [PubMed](#)
14. Liu F, et al. 2020. *J Immunother Cancer.* 8:. [PubMed](#)
15. O'Boyle KC, et al. 2020. *Methods Mol Biol.* 2111:1. [PubMed](#)
16. Cobb DA, et al. 2022. *J Immunother Cancer.* 10:. [PubMed](#)
17. Mirzaei R, et al. 2021. *Sci Adv.* 7:eabh2148. [PubMed](#)
18. Del Alcazar D, et al. 2019. *Cell Rep.* 28:3047. [PubMed](#)
19. Tocheva AS, et al. 2020. *J Biol Chem.* 295:18036. [PubMed](#)
20. Gee MH, et al. 2018. *Cell.* 172:549. [PubMed](#)
21. Conrad J, et al. 2012. *J Virol.* 86:4213. [PubMed](#)
22. Muhammad F, et al. 2020. *J Autoimmun.* 111:102441. [PubMed](#)
23. Macmillan ML, et al. 2021. *Blood Adv.* 5:1425. [PubMed](#)
24. Zahn R, et al. 2008. *J Virol.* 82:11577. [PubMed](#)
25. Schwabenland M, et al. 2021. *Immunity.* . [PubMed](#)
26. Bengsch B et al. 2018. *Immunity.* 48(5):1029-1045. [PubMed](#)
27. Stervbo U, et al. 2019. *Front Immunol.* 0.949305556. [PubMed](#)
28. Anna F, et al. 2021. *J Immunother Cancer.* 9:. [PubMed](#)
29. Saber MM, et al. 2022. *Antibodies (Basel).* 11:. [PubMed](#)
30. Kim MH, et al. 2018. *Cancer Immunol Res.* 0.427083333. [PubMed](#)
31. Conrad J, et al. 2011. *J Immunol.* 186:6871. [PubMed](#)
32. Monteiro P, et al. 2011. *J Immunol.* 186:4618. [PubMed](#)
33. Stensland ZC, et al. 2022. *iScience.* 25:103626. [PubMed](#)
34. Kim A, et al. 2019. *J Immunol.* 203:1076. [PubMed](#)
35. Lewinsky H, et al. 2018. *J Clin Invest.* 128:5465. [PubMed](#)
36. Vojnov L, et al. 2010. *J Virol.* 84:753. [PubMed](#)
37. Tang X, et al. 2020. *Sci Adv.* 6:eaaz0374. [PubMed](#)
38. Nicholas K, et al. 2015. *Cytometry A.* 10.1002/cyto.a.22799. [PubMed](#)
39. Enyindah-Asonye G, et al. 2019. *Front Immunol.* 10:511. [PubMed](#)
40. Lavin Y et al. 2017. *Cell.* 169(4):750-765. [PubMed](#)
41. Hwang HJ, et al. 2021. *Immun Inflamm Dis.* 9:274. [PubMed](#)
42. Chiou SH, et al. 2021. *Immunity.* 54:586. [PubMed](#)

RRID AB\_940488 (BioLegend Cat. No. 329902)

## Antigen Details

<b>Structure</b>	Immunoglobulin superfamily
<b>Distribution</b>	Transiently expressed on CD4 <sup>+</sup> CD8 <sup>-</sup> thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells
<b>Ligand/Receptor</b>	B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
<b>Cell Type</b>	B cells, Lymphocytes, T cells, Thymocytes, Tregs
<b>Biology Area</b>	Cancer Biomarkers, Immunology, Inhibitory Molecules
<b>Molecular Family</b>	CD Molecules, Immune Checkpoint Receptors
<b>Gene ID</b>	<a href="#">5133</a>

## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

---

Brilliant Violet 421™ anti-human CD279 (PD-1), Purified anti-human CD279 (PD-1), FITC anti-human CD279 (PD-1), PE anti-human CD279 (PD-1), APC anti-human CD279 (PD-1), Alexa Fluor® 647 anti-human CD279 (PD-1), PerCP/Cyanine5.5 anti-human CD279 (PD-1), APC/Cyanine7 anti-human CD279 (PD-1), Pacific Blue™ anti-human CD279 (PD-1), PE/Cyanine7 anti-human CD279 (PD-1), Purified anti-human CD279 (PD-1) (Maxpar® Ready), Brilliant Violet 605™ anti-human CD279 (PD-1), Ultra-LEAF™ Purified anti-human CD279 (PD-1), Brilliant Violet 711™ anti-human CD279 (PD-1), Brilliant Violet 785™ anti-human CD279 (PD-1), Brilliant Violet 510™ anti-human CD279 (PD-1), Biotin anti-human CD279 (PD-1), PE/Dazzle™ 594 anti-human CD279 (PD-1), Alexa Fluor® 488 anti-human CD279 (PD-1), PerCP anti-human CD279 (PD-1), GoInVivo™ Purified anti-human CD279 (PD-1), Brilliant Violet 650™ anti-human CD279 (PD-1), Alexa Fluor® 700 anti-human CD279 (PD-1), APC/Fire™ 750 anti-human CD279 (PD-1), TotalSeq™-A0088 anti-human CD279 (PD-1), TotalSeq™-B0088 anti-human CD279 (PD-1), TotalSeq™-C0088 anti-human CD279 (PD-1), Brilliant Violet 750™ anti-human CD279 (PD-1), TotalSeq™-D0088 anti-human CD279 (PD-1), PE/Fire™ 640 anti-human CD279 (PD-1), PE/Cyanine5 anti-human CD279 (PD-1)

## Product Data

---



PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with purified CD279 (clone EH12.2H7) (filled histogram), or purified mouse IgG1, κ (open histogram), followed by anti-mouse IgG FITC.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587